Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT

Journal of Hypertension

Volumn 32, Issue 7, 2014, Pages 1503-1513

  Reisin, Efrain ^a   Graves, John W ^b   Yamal, José Miguel ^c   Barzilay, Joshua I ^d   Pressel, Sara L ^c   Einhorn, Paula T ^e   Dart, Richard A ^f   Retta, Tamrat M ^g   Saklayen, Mohammad G ^h   Davis, Barry R ^c  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f MARSHFIELD CLINIC   (United States)

^g HOWARD UNIVERSITY HOSPITAL   (United States)

^h WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Blood pressure control; Hypertension; Obesity; Overweight

Indexed keywords

AMLODIPINE; CHLORTALIDONE; LISINOPRIL; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CHLORTHALIDONE; COHORT STUDIES; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PROSPECTIVE STUDIES;

EID: 84903895488     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000204     Document Type: Article

References (30)

1. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 8:605-619
2. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. J Am Med Assoc 1978; 240:1607-1610
3. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs. a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816
4. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906
5. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensinreceptor blocker. N Engl J Med 2006; 354:1685-1697
6. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013; 381:537-545
7. Weber MA, Bakris GL, Dahlof B, Pitt B, Velazquez E, Gupte J, et al. Baseline characteristics in the Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press 2007; 16:13-19
8. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34:2159-2219
9. Jordan J, Yumuk V, Schlaich M, Nilsson PM, Zahorska-Markiewicz B, Grassi G, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 2012; 30:1047- 1055
10. Bramlage P, PittrowD, WittchenHU, KirchW,Boehler S, Lehnert H, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004; 17:904-910
11. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich) 2013; 15:14-33
12. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187
13. Cushman WC, Ford CE, Einhorn PT, Wright JT Jr, Preston RA, Davis BR, et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2008; 10:751-760
14. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Protocol. Last updated May 2000. https://allhat.sph.uth.tmc. edu/Forms/protocol.pdf. [Accessed 19 April 2012]
15. Extension Protocol: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Last updated August 31, 2007. https://allhat.sph. uth.tmc.edu/Forms/ExtensionProtocol.pdf. [Accessed 18 April 2012]
16. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. Rationale and design for the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9:342-360
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997
18. Wright JT Jr, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008; 168:207-217
19. Black HR, Davis BR, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 31:353-360
20. Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, et al. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J 2007; 153:42-53
21. National Kidney Foundation. GFR calculators: serum creatinine and cystatin C (2012) (With SI Units). http://www.kidney.org/professionals/kdoqi/ gfr-calculator.cfm. [Accessed 12 July 2013]
22. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43:4-9
23. Wassertheil-Smoller S, Fann C, Allman RM, Black HR, Camel GH, Davis B, et al. Relation of low body mass to death and stroke in the Systolic Hypertension in the Elderly Program. The SHEP Cooperative Research Group. Arch Intern Med 2000; 160:494-500
24. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428
25. Wright JT Jr, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169:832-842
26. Einhorn PT, Davis BR, Wright JT Jr, Rahman M, Whelton PK, Pressel SL, ALLHAT Cooperative Research Group. ALLHAT: still providing correct answers after 7 years. Curr Opin Cardiol 2010; 25:355-365
27. Proschan M, Ford CE, Cutler JA, Graumlich JF, Pavlik V, Cushman WC, et al. How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? Stat Med 2012; 32:884-897
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC-7 report. JAMA 2003; 289:2560-2572
29. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640- 1649
30. Shah RV, Abbasi SA, Yamal J, Davis BR, Barzilay J, Einhorn PT, Goldfine A, The ALLHAT Collaborative Research Group. Impaired fasting glucose and body mass index as determinants of mortality in ALLHAT: Is the obesity paradox real? J Clinical Hypertens 2014. DOI: 10.1111/ jch.12325; (in press).